MinervaX ApS has developed a vaccine that uses a single fusion protein to trigger an immune response that could target more than 95% of Group B Streptococcus strains. The preclinical candidate could provide greater protection than other GBS vaccines in development and could reduce infection-related complications in newborns.

According to CEO Per Fischer, at any given time about 15-25% of women are spontaneously colonized with different strains of Group B Streptococcus (GBS) in their birth canal. While it is harmless to the mother, colonization during pregnancy can lead to life-threatening infections in newborns, such as meningitis or sepsis, as well as in utero complications, including premature birth or stillbirth.